Delayed time to radiation and overall survival in Merkel cell carcinoma

被引:2
|
作者
Ma, Kevin L. [1 ]
Sharon, Cimarron E. [1 ]
Tortorello, Gabriella N. [1 ]
Keele, Luke [2 ]
Lukens, John N. [3 ]
Karakousis, Giorgos C. [1 ,4 ]
Miura, John T. [1 ]
机构
[1] Hosp Univ Penn, Dept Surg, Philadelphia, PA USA
[2] Hosp Univ Penn, Dept Epidemiol & Biostat, Philadelphia, PA USA
[3] Hosp Univ Penn, Dept Radiat Oncol, Philadelphia, PA USA
[4] Hosp Univ Penn, Dept Surg, 3400 Spruce St, Silverstein 4, Philadelphia, PA 19104 USA
关键词
cutaneous malignancies; Merkel cell carcinoma; radiation therapy;
D O I
10.1002/jso.27421
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Clinically localized Merkel cell carcinoma (MCC) is commonly treated with surgical excision and radiotherapy. The relationship between time to adjuvant radiotherapy and overall survival (OS) remains understudied.Methods: This retrospective study used data from the National Cancer Database (2006-2019). Patients with clinically localized MCC who received surgical excision and adjuvant radiotherapy were included. Multivariate regressions were used to account for various patient and tumor factors. The primary outcome was 5-year OS, and the secondary outcome was time from diagnosis to adjuvant radiation (TTR).Results: Of the 1965 patients included, most were male (n = 1242, 63.2%) and white (n = 1915, 97.5%), and the median age was 74 years (interquartile range [IQR]: 66-81). The median TTR was 83 days (IQR: 65-106). A total of 83.6% of patients received radiotherapy to the primary site, 21.3% to the draining nodal basin, 17.1% to both, and 12.2% whose target location of radiotherapy was not recorded in the data. TTR of =79 days (the 45th percentile) was associated with worse OS on both univariate and multivariate analyses (log-rank p = 0.0014; hazard ratio [HR]: 1.258, 95% confidence interval [CI]: 1.055-1.500, p = 0.010). This persisted on sub-analyses of patients <80 years old (n = 1407; HR: 1.380, 95% CI: 1.080-1.764, p = 0.010) and of patients with Charlson comorbidity index (CCI) of 0 (n = 1411; HR: 1.284, 95% CI: 1.034-1.595, p = 0.024). Factors associated with delayed TTR included greater age (p = 0.039), male sex (p = 0.04), CCI > 1 (p = 0.036), academic facility (p < 0.001), rural county (p = 0.034), AJCC T2 stage (p = 0.010), negative margins (p = 0.017), 2+ pathologically positive regional nodes (p = 0.011), and margin size >2 cm (p = 0.015).Conclusions: Delayed radiotherapy (=79 days) was associated with worse OS of MCC patients. Further study in controlled cohorts is needed to ascertain this relationship.
引用
收藏
页码:1385 / 1393
页数:9
相关论文
共 50 条
  • [41] Histopathologic Features for Overall Survival in Merkel Cell Carcinoma: A Case Series with Intact Mismatch Repair Protein Expression
    Kestel, Selin
    Ogut, Betul
    Inan, Mehmet Arda
    Erdem, Ozlem
    TURKISH JOURNAL OF PATHOLOGY, 2023, 39 (03) : 169 - 178
  • [42] Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma
    Sandra P. D’Angelo
    Matthias Hunger
    Andrew S. Brohl
    Paul Nghiem
    Shailender Bhatia
    Omid Hamid
    Janice M. Mehnert
    Patrick Terheyden
    Kent C. Shih
    Isaac Brownell
    Céleste Lebbé
    Karl D. Lewis
    Gerald P. Linette
    Michele Milella
    Michael Schlichting
    Meliessa H. Hennessy
    Murtuza Bharmal
    Cancer Immunology, Immunotherapy, 2019, 68 : 609 - 618
  • [43] Merkel cell carcinoma: a prompt diagnosis to increase survival
    Chessa, M. A.
    Malosso, M.
    Pepe, F.
    Patrizi, A.
    Telo, S.
    Ambrosini, V.
    Fanti, S.
    Magnano, M.
    Baraldi, C.
    Corti, B.
    Filippi, F.
    Vaccari, S.
    Pileri, A.
    Bardazzi, F.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (12) : E478 - E480
  • [44] Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma
    D'Angelo, Sandra P.
    Hunger, Matthias
    Brohl, Andrew S.
    Nghiem, Paul
    Bhatia, Shailender
    Hamid, Omid
    Mehnert, Janice M.
    Terheyden, Patrick
    Shih, Kent C.
    Brownell, Isaac
    Lebbe, Celeste
    Lewis, Karl D.
    Linette, Gerald P.
    Milella, Michele
    Schlichting, Michael
    Hennessy, Meliessa H.
    Bharmal, Murtuza
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (04) : 609 - 618
  • [45] MODELLING OVERALL SURVIVAL IN IMMUNOTHERAPY USING PARAMETRIC TECHNIQUES: AVELUMAB IN PREVIOUSLY TREATED METASTATIC MERKEL CELL CARCINOMA
    Bullement, A.
    Amin, A.
    Stapelkamp, C.
    Willis, A.
    Lilley, C.
    Hatswell, A. J.
    Pescott, C.
    Bharmal, M.
    VALUE IN HEALTH, 2018, 21 : S11 - S11
  • [46] Sentinel lymph node positivity and overall survival in immunosuppressed patients with Merkel cell carcinoma: a national cohort study
    Song, Y.
    Zheng, C.
    Shannon, A. B.
    Fraker, D. L.
    Miura, J. T.
    Karakousis, G. C.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (03) : 569 - 571
  • [47] Association Between Surgical Margins Larger Than 1 cm and Overall Survival in Patients With Merkel Cell Carcinoma
    Andruska, Neal
    Fischer-Valuck, Benjamin W.
    Mahapatra, Lily
    Brenneman, Randall J.
    Gay, Hiram A.
    Thorstad, Wade L.
    Fields, Ryan C.
    MacArthur, Kelly M.
    Baumann, Brian C.
    JAMA DERMATOLOGY, 2021, 157 (05) : 540 - 548
  • [48] Radiation Therapy Influences Outcomes in Merkel Cell Carcinoma
    Strom, T.
    Carr, M.
    Zager, J. S.
    Smith, F.
    Cruse, C. W.
    Messina, J. L.
    Padhya, T. A.
    Rao, N. G.
    Sondak, V. K.
    Harrison, L. B.
    Trotti, A.
    Caudell, J. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E631 - E631
  • [49] Mild Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
    Matsui, Toshiaki
    Okano, Naoko
    Kawamura, Hidemasa
    Oike, Takahiro
    Ohno, Tatsuya
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (01)
  • [50] Chronic mTOR activation promotes cell survival in Merkel cell carcinoma
    Lin, Zhenyu
    McDermott, Amelia
    Shao, Lijian
    Kannan, Aarthi
    Morgan, Michael
    Stack, Brendan C., Jr.
    Moreno, Mauricio
    Davis, Daniel A.
    Cornelius, Lynn A.
    Gao, Ling
    CANCER LETTERS, 2014, 344 (02) : 272 - 281